Eli Lilly said its triple-agonist retatrutide cleared the primary endpoints in two Phase 3 obesity trials, but the company also acknowledged the cardiovascular risk reduction signal was less clear than in earlier studies. The results set up regulatory steps, with Lilly saying it plans to file for approval in early 2027. Separately, Lilly also provided additional context on how the trial outcomes translated into weight-loss magnitude versus prior programs, while the cardiovascular endpoint remains the key question for payers and guideline committees assessing long-term risk reduction. (Retatrutide is the GLP-1/GIP/glucagon-pathway triple agonist.)